|Click here for details on how to download this file |
We've only scratched the surface on understanding the JAK/STAT pathway's role in atopic dermatitis (AD)
Key cytokines, including IL-4, IL-13, IL-22, IL-31, and TSLP, contribute to this chronic, relapsing-remitting inflammatory skin disease. Many of these cytokines are also thought to contribute to itch, a symptom responsible for much of the disease burden.
By inhibiting the JAK/STAT pathway, it may be possible to decrease signaling of key cytokines that drive AD inflammation, itch, and skin barrier disruption.
IL=interleukin; JAK=Janus kinase; STAT=signal transducer and activator of transcription; TSLP=thymic stromal lymphopoietin.
Let's explore more about the JAK/STAT pathway at scratchingtheADsurface.com
Pfizer does not currently have any JAK inhibitors approved for the treatment of AD.
References: 1. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130 (6):1344-1354. 2. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70 (2):338-351. 3. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71 (2):327-349. 4. Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46 (12):1053-1101. 5. Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140 (3):633-643. 6. Hammarén HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKS in cytokine signaling and its breakdown in disease. Cytokine. 2019;118:48-63.
PP-A2D-USA-0158-02 © 2020 Pfizer Inc. All rights reserved. December 2020
Target: Healthcare Professional (HCP)
Dermatology Times - Vol 42 - No 3 - March 2021
Other ads from this brand
|Rate this file (No vote yet)|